| 44 | 0 | 72 |
| 下载次数 | 被引频次 | 阅读次数 |
<正>米达替尼(mirdametinib)是由Spring Works Therapeutics公司研发的一种小分子丝裂原活化蛋白激酶1和2(MEK1/2)抑制剂,于2025年2月11日经美国FDA批准上市,商品名为Gomekli~[1],用于治疗患有1型神经纤维瘤病相关的丛状神经纤维瘤的成人和儿童(2岁及以上)患者。
Abstract：[1] US FDA.FDA approved drug products[EB/OL].[2025-02-11].https://www.fda.gov/drugs/resources-information-approved-drugs/FDA approves mirdametinib for adult and pediatric patients with neurofibromatosis type1 who have symptomatic plexiform neurofibromas not amenable to complete resection.
[2] IRDAM E A,NANNINGA T N,DAVI E M,et al.Methods of preparing a phenylamino benzamide as an MEK inhibitor:WO,2006134469 A1[P].2006-12-21.
[3] MOERTEL C L,HIRBE A C,SHUHAIBER H H,et al.ReNeu:a pivotal,phase IIb trial of mirdametinib in adults and children with symptomatic neurofibromatosis type 1-associated plexiform neurofibroma[J].J Clin Oncol,2025,43(6):716-729.
[4] ARMSTRONG A E,BELZBERG A J,CRAWFORD J R,et al.Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas[J].BMC Cancer,2023,23(1):553.
基本信息:
DOI：10.14142/j.cnki.cn21-1313/r.2026.01.009
中图分类号:R979.1
引用信息:
[1]吕佳榆.米达替尼(Mirdametinib, Gomekli)[J].中国药物化学杂志,2026,36(01):82.DOI:10.14142/j.cnki.cn21-1313/r.2026.01.009.
2026-02-25
2026-02-25